Moderna stock on track for the eighth consecutive day of losses
Moderna shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost about 29.6% in the last 12 months and YTD, the stock is trailing slightly behind the broader S&P 500 market which rose 5.06% as compared to MRNA’s gain of 2.56%.
Looking at Seeking Alpha's Quant Ratings, this Massachusetts-based company has a Hold rating with a score of 2.61 out of 5.
When it comes to Wall Street analysis, 10 out of 26 analysts recommend a Hold, 9 rate it as a Hold, 4 rate it a Buy, 2 rate it as a Strong Sell and 1 recommends Sell.
Seeking Alpha analysts have a Hold rating on the company.
SA analyst The Value Portfolio said, “Moderna's financial picture remains volatile, but it has a strong cash position and is investing heavily in R&D to build new businesses.
The company had a weaker 2023 as demand for COVID-19 vaccines dropped. However, it still expects reasonable revenue in 2024 with ~$4 billion in revenue most in the fall. It's important for the company to see its other businesses ramp up in 2024-2025, specifically its RSV and Flu businesses.”
Moderna is expected to post its Q1 earnings next month, and analysts are expecting a loss of $3.55 per share on revenue of $125.33M.
April 22, 2024
